Food and Drug Administration

Vaccines and Related Biological Products Advisory Committee

November 17, 2005

Briefing Information

Developing New Pneumococcal Vaccines Indicated for Adults for US Licensure - Pre-meeting Package (PDF)


The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

GlaxoSmithKline Briefing Document (PDF)

Pneumococcal Conjugate Vaccine Adult Program, Wyeth Vaccines (PDF)

Pneumovax 23™, Merck & Co., Inc. - Cover Page (PDF)

Protection of Adults From Invasive Pneumococcal Disease (IPD) by Means of Active Immunization With Currently Licensed Vaccine Pneumovax 23™ (PPV23), Merck & Co., Inc. (PDF)